Novartis AG (NVS) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer PR...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

October 3, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: Pharmaceutical companies are demonstrating innovation by...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

LEXINGTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a...

Lindy Biosciences stringe un accordo di licenza e collaborazione con Novartis per la somministrazione innovativa di farmaci multitarget

Novartis si assicura i diritti esclusivi globali alla tecnologia di microglassification di Lindy Biosciences in diversi target biologici La...

Lindy Biosciences conclut un accord de licence et de collaboration avec Novartis pour l’innovation en matière d’administration de médicaments à cibles multiples

Novartis obtient les droits mondiaux exclusifs sur la technologie de microglassification de Lindy Biosciences pour de multiples cibles...

Lindy Biosciences schließt Lizenzierungs- und Kooperationsvereinbarung mit Novartis für Wirkstoffabgabeinnovation für mehrere Zielmoleküle ab

Novartis sichert sich die weltweiten Exklusivrechte an der Mikroverglasungstechnologie von Lindy Biosciences für mehrere biologische...